NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

InflaRx N.V (XETRA: IF0)

 
IF0 Technical Analysis
4
As on 12th Aug 2022 IF0 STOCK Price closed @ 2.94 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.13 & Strong Sell for SHORT-TERM with Stoploss of 3.79 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

IF0STOCK Price

Open 2.94 Change Price %
High 2.94 1 Day -0.07 -2.33
Low 2.94 1 Week 0.18 6.52
Close 2.94 1 Month 1.59 117.78
Volume 3 1 Year -1.76 -37.45
52 Week High 5.28 | 52 Week Low 0.94
 
XETRA Germany Most Active Stocks
LHAR 2.05 -20.23%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BVBA 0.02 -60.00%
SNH 0.16 6.67%
SNH 0.16 6.67%
SNH 0.16 6.67%
AT1 1.15 5.50%
AT1 1.15 5.50%
 
XETRA Germany Top Gainers Stocks
ASKN 0.73 73.81%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
 
XETRA Germany Top Losers Stocks
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
BVBA 0.02 -60.00%
SD1 0.13 -51.85%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
CNW 0.24 -29.41%
 
 
IF0
Daily Charts
IF0
Intraday Charts
Whats New @
Bazaartrend
IF0
Free Analysis
 
IF0 Important Levels Intraday
RESISTANCE2.94
RESISTANCE2.94
RESISTANCE2.94
RESISTANCE2.94
RESISTANCE2.94
RESISTANCE2.94
RESISTANCE2.94
RESISTANCE2.94
 
IF0 Forecast May 2024
4th UP Forecast6.18
3rd UP Forecast5.14
2nd UP Forecast4.5
1st UP Forecast3.86
1st DOWN Forecast2.02
2nd DOWN Forecast1.38
3rd DOWN Forecast0.74
4th DOWN Forecast-0.3
 
IF0 Weekly Forecast
4th UP Forecast4.19
3rd UP Forecast3.79
2nd UP Forecast3.54
1st UP Forecast3.29
1st DOWN Forecast2.59
2nd DOWN Forecast2.34
3rd DOWN Forecast2.09
4th DOWN Forecast1.69
 
IF0 Forecast2024
4th UP Forecast11.46
3rd UP Forecast8.73
2nd UP Forecast7.04
1st UP Forecast5.35
1st DOWN Forecast0.53
2nd DOWN Forecast-1.16
3rd DOWN Forecast-2.85
4th DOWN Forecast-5.58
 
 
IF0 Other Details
Segment EQ
Market Capital 119303016.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
IF0 Address
IF0
 
IF0 Latest News
 
Your Comments and Response on InflaRx N.V
 
IF0 Business Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service